Company intelligence / Profile preview

Wision A.I.

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Wision A.I.'s EndoScreener, a deep learning-based AI tool for real-time polyp detection during colonoscopy, demonstrated reduction of adenoma miss rate from over 31% to 20% and approximately 32% more polyps detected versus standard colonoscopy; the tool received both FDA 510(k) clearance and CE mark based on multi-center clinical studies[1][2][3].

Therapeutic areas: GastroenterologyOncology
Modalities: DeviceSoftwareArtificial intelligence
Industry: Digital Health Medical Devices

Partnerships

Micro-Tech Endoscopy USA (exclusive US GI endoscopy distributor for EndoScreener)[2]

Beyond the preview

Go deeper on Wision A.I..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wision A.I..

Explore the full profile